Our Mission
PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
Opdivo (Nivolumab) for Cancer: What Patients Need to Know
Opdivo (Nivolumab) for Cancer: What Patients Need to Know. Learn how Opdivo (nivolumab) works, which cancers it treats, common side effects, immune-related complications, and evidence-based complementary therapies that may help cancer patients tolerate treatment.
One of the biggest misconceptions about immunotherapy is that fewer side effects mean the treatment isn’t working. Fortunately, research does not support that belief. Some patients achieve excellent, long-lasting responses with minimal side effects, while others develop significant immune-related complications. Side effects are a sign of immune activation—but not necessarily a measure of how well the cancer is responding.
I am a long-term survivor of an incurable blood cancer called multiple myeloma. My research and experience with evidence-based non-conventional therapies are the reason why I have lived in complete remission from my incurable blood cancer since achieving complete remission in early 1999. I have learned that the best way to manage cancer is to combine the best of conventional and evidence-based non-conventional therapies.
I have come to believe that therapy-induced side effects can be life-threatening while ruining quality of life. Consider therapies shown to reduce possible side effects.
Before beginning Opdivo (Nivolumab) for cancer, consider:
Scroll down the page and post a question or a comment if there’s anything you’d like to know about carboplatin + paclitaxel for cancer.
Good luck,
David Emerson
Concepts Central to Managing Your Cancer-
- Integrative Oncology: Combining Conventional and Natural Cancer Therapies
- Complementary Cancer Therapies: Evidence-based
- Immunotherapy for Cancer: What Patients Need to Know Before, During, and After Treatment
- Managing Cancer Treatment Side Effects: An Evidence-Based Guide to Prevention, Relief, and Recovery
- Cancer Financial Toxicity: Costs, Medical Debt, Insurance, Financial Assistance, and Survivorship
What Is Opdivo?
Receiving a cancer diagnosis is overwhelming enough without having to learn an entirely new language of medications, biomarkers, and treatment options. If your oncologist has recommended Opdivo® (nivolumab), you’ve probably heard it described as immunotherapy rather than chemotherapy.
That’s an important distinction.
Unlike chemotherapy, which attacks rapidly dividing cells directly, Opdivo helps your own immune system recognize and destroy cancer cells. It belongs to a class of medications called immune checkpoint inhibitors, drugs that have dramatically changed treatment for melanoma, lung cancer, kidney cancer, bladder cancer, Hodgkin lymphoma, head and neck cancer, esophageal cancer, and several other malignancies.
For some patients, Opdivo has produced responses lasting years—even after treatment has stopped. Unfortunately, not everyone benefits, and because the immune system is being stimulated, treatment can sometimes cause inflammation in healthy organs.
Understanding both the benefits and the risks allows patients to recognize problems early and work with their oncology team to manage side effects before they become serious.
Quick Facts
| Drug Name | Opdivo |
|---|---|
| Generic name | Nivolumab |
| Drug class | PD-1 immune checkpoint inhibitor |
| Type of therapy | Immunotherapy |
| Administration | Intravenous infusion |
| Typical infusion schedule | Every 2, 4, or 6 weeks (depending on indication) |
| FDA approval | First approved in 2014 |
| Manufacturer | Bristol Myers Squibb |
Table of Contents
- What is Opdivo?
- How does Opdivo work?
- Which cancers does Opdivo treat?
- How effective is Opdivo?
- Benefits of treatment
- Possible side effects
- Serious immune-related adverse events
- Complementary therapies that may help
- Questions to ask your oncologist
- Frequently Asked Questions
- Research and references
How Does Opdivo Work?
Your immune system constantly searches for abnormal cells.
Cancer cells survive because they learn how to “hide” from immune attack.
One of the most important escape mechanisms involves a protein called PD-1 (Programmed Death-1) located on T-cells.
Normally:
- PD-1 prevents excessive immune reactions.
- Healthy tissues use this system to avoid autoimmune damage.
- Cancer cells exploit this pathway to shut down immune attack.
Opdivo blocks PD-1.
Once the “off switch” is removed:
- T-cells recognize cancer cells more effectively.
- The immune system attacks tumors.
- Some patients experience long-lasting immune memory that continues even after therapy ends.
Unlike chemotherapy, which kills cancer cells directly, Opdivo empowers your immune system to do the work.
Opdivo (Nivolumab) for Cancer
Which Cancers Is Opdivo Approved to Treat?
Opdivo is approved—alone or in combination with other therapies—for numerous cancers, including:
Melanoma
One of the earliest and most successful uses of Opdivo.
Patients with advanced melanoma now frequently survive many years thanks to checkpoint inhibitors.
Non-Small Cell Lung Cancer (NSCLC)
Opdivo may be used:
- after chemotherapy
- before surgery
- after surgery
- together with chemotherapy
- together with Yervoy (ipilimumab)
depending upon disease stage.
Kidney Cancer (Renal Cell Carcinoma)
Often combined with:
- Yervoy (ipilimumab)
- Cabometyx (cabozantinib)
to improve survival.
Bladder Cancer
Approved for certain patients with urothelial carcinoma, particularly in advanced or metastatic disease.
Head and Neck Cancer
Used when recurrent or metastatic disease progresses following platinum-based chemotherapy.
Esophageal Cancer
Increasingly used before surgery or after surgery depending upon tumor characteristics.
Gastric and Gastroesophageal Junction Cancer
Often combined with chemotherapy.
Colorectal Cancer
Patients with:
- MSI-H
- dMMR
tumors may experience dramatic responses because these cancers are especially sensitive to immune checkpoint inhibition.
Classical Hodgkin Lymphoma
One of the cancers with the highest response rates to PD-1 inhibitors after relapse.
Other FDA-approved indications include
- Mesothelioma
- Hepatocellular carcinoma
- Urothelial carcinoma
- Certain skin cancers
- Additional indications continue to expand as new clinical trial data become available.
How Effective Is Opdivo?
Like Keytruda, Opdivo has transformed outcomes for several cancers that once had very poor prognoses.
Clinical trials have shown that Opdivo can:
- improve overall survival
- delay disease progression
- produce durable responses lasting years
- improve quality of life compared with chemotherapy in selected cancers
- reduce recurrence risk when used after surgery for some cancers
Perhaps the most remarkable aspect of checkpoint inhibitors is that some patients remain cancer-free long after treatment has stopped, suggesting that the immune system has developed a lasting memory against the cancer.
Unfortunately, responses vary widely.
Some patients experience dramatic tumor shrinkage, while others derive little benefit. Researchers continue to study biomarkers—including PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI-H/dMMR)—to better predict who is most likely to respond.
Opdivo (Nivolumab) for Cancer
Potential Benefits of Opdivo
Compared with conventional chemotherapy, Opdivo may offer several advantages for appropriate patients:
- Durable responses in some cancers
- Longer overall survival in many approved indications
- Fewer traditional chemotherapy side effects such as hair loss and severe nausea
- Outpatient treatment with infusions every 2–6 weeks
Can often be combined with chemotherapy, targeted therapy, or other immunotherapies
- Potential for long-term immune memory against cancer
- However, because Opdivo activates the immune system rather than directly attacking cancer cells, it comes with a different side-effect profile. Instead of causing low blood counts or hair loss, it can trigger inflammation in healthy tissues—a group of complications known as immune-related adverse events (irAEs).
Recognizing these side effects early is one of the most important ways patients can improve the safety of treatment.
Opdivo (Nivolumab) for Cancer
Opdivo Side Effects: What to Expect and How to Manage Them
Unlike chemotherapy, which directly damages rapidly dividing cells, Opdivo stimulates the immune system.
That means many patients avoid classic chemotherapy side effects like hair loss or severe nausea. However, because Opdivo removes one of the immune system’s natural “brakes,” immune cells may mistakenly attack healthy organs.
These complications are called immune-related adverse events (irAEs).
Most are mild and reversible if recognized early. A small percentage become serious or even life-threatening if ignored.
The key message: Never wait several days to report new symptoms. Early treatment—often with corticosteroids or temporarily stopping immunotherapy—can prevent long-term complications.
Common Side Effects of Opdivo
Most patients experience at least one mild side effect during treatment.
| Side Effect | Approximate Frequency | Usually Manageable? |
|---|---|---|
| Fatigue | ★★★★★ Very common | Yes |
| Skin rash | ★★★★☆ | Usually |
| Itching | ★★★★☆ | Usually |
| Diarrhea | ★★★☆☆ | Usually |
| Nausea | ★★★☆☆ | Usually |
| Loss of appetite | ★★★☆☆ | Yes |
| Joint pain | ★★★☆☆ | Usually |
| Muscle aches | ★★★☆☆ | Usually |
| Mild cough | ★★☆☆☆ | Sometimes |
| Infusion reactions | ★☆☆☆☆ | Yes with monitoring |
Unlike chemotherapy, hair loss is uncommon unless Opdivo is given together with chemotherapy.
Serious Immune-Related Side Effects
Although uncommon, these are the complications every patient should understand before beginning treatment.
Lungs (Pneumonitis)
Inflammation of lung tissue.
Symptoms
- Persistent cough
- Shortness of breath
- Chest pain
- Difficulty exercising
- Fever
Why It Matters
Pneumonitis is one of the leading reasons immunotherapy must be stopped.
Early steroid treatment often reverses inflammation.
Opdivo (Nivolumab) for Cancer
Colon (Colitis)
Inflammation of the large intestine.
Symptoms
- Frequent diarrhea
- Bloody stool
- Abdominal cramping
- Severe dehydration
Patients should never assume persistent diarrhea is “just something I ate.”
Liver (Hepatitis)
Often discovered on routine blood work before symptoms develop.
Possible symptoms include
- Yellow skin
- Dark urine
- Abdominal pain
- Fatigue
- Easy bruising
Regular liver function testing helps detect problems early.
Thyroid Problems
One of the most common immune-related toxicities.
Patients may first develop:
Hyperthyroidism
- Anxiety
- Tremor
- Weight loss
- Rapid heartbeat
Later this frequently changes into:
Hypothyroidism
- Fatigue
- Weight gain
- Constipation
- Feeling cold
- Depression
Many patients simply require lifelong thyroid replacement medication.
Pituitary Gland (Hypophysitis)
Inflammation of the pituitary gland can disrupt multiple hormones.
Symptoms include:
- Severe fatigue
- Headaches
- Low blood pressure
- Dizziness
- Nausea
- Vision changes
Because symptoms resemble ordinary cancer fatigue, diagnosis is sometimes delayed.
Adrenal Insufficiency
Although rare, adrenal inflammation can become an emergency.
Symptoms include
- Extreme weakness
- Vomiting
- Severe dizziness
- Low blood pressure
- Confusion
Immediate medical evaluation is required.
Pancreatitis
Inflammation of the pancreas may present with
- Severe upper abdominal pain
- Nausea
- Vomiting
- Elevated pancreatic enzymes
Kidney Inflammation (Nephritis)
Symptoms may include
- Swelling
- Elevated creatinine
- Reduced urine output
- High blood pressure
Routine laboratory monitoring usually detects kidney inflammation before symptoms become severe.
Type 1 Diabetes
Checkpoint inhibitors occasionally trigger autoimmune destruction of insulin-producing cells.
Symptoms
- Excessive thirst
- Frequent urination
- Weight loss
- Blurred vision
Immediate treatment is necessary.
Skin Reactions
Most skin reactions are mild.
Rarely, patients develop severe blistering disorders such as:
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
These require emergency care.
Neurologic Toxicities
Rare but potentially serious.
Symptoms include
- Muscle weakness
- Double vision
- Difficulty walking
- Numbness
- Facial weakness
- Confusion
Cardiac Toxicity (Myocarditis)
Although uncommon, myocarditis is among the most dangerous immune-related side effects.
Symptoms include
- Chest pain
- Shortness of breath
- Palpitations
- Fainting
Patients with pre-existing cardiovascular disease should promptly report new symptoms.
When Should You Call Your Oncology Team?
Call your oncology office immediately if you experience:
- New shortness of breath
- Persistent diarrhea
- Bloody stools
- Severe abdominal pain
- Yellow eyes or skin
- Fever
- Confusion
- Chest pain
- New muscle weakness
- Severe headaches
- Vision changes
Do not wait until your next scheduled infusion.
Can Complementary Therapies Help?
Many complementary therapies may improve quality of life without reducing Opdivo’s anti-cancer effects, although patients should always discuss supplements with their oncology team.
Current evidence supports several non-drug strategies for managing common symptoms.
Evidence-Based Integrative Therapies for Common Side Effects
| Side Effect | Complementary Therapy | Evidence* |
|---|---|---|
| Fatigue | Walking/exercise program | ★★★★★ |
| Fatigue | Resistance training | ★★★★★ |
| Anxiety | Mindfulness meditation | ★★★★★ |
| Sleep problems | Cognitive Behavioral Therapy for Insomnia (CBT-I) | ★★★★★ |
| Stress | Yoga | ★★★★☆ |
| Anxiety | Tai Chi | ★★★★☆ |
| Muscle pain | Acupuncture | ★★★★☆ |
| Joint pain | Omega-3 fatty acids† | ★★★☆☆ |
| Constipation | Fiber + hydration | ★★★★★ |
| Appetite | Mediterranean diet | ★★★★☆ |
| General health | Anti-inflammatory diet | ★★★★☆ |
*Evidence ratings reflect the strength of published evidence for symptom management, not cancer treatment efficacy.
†Discuss omega-3 supplements with your oncology team if you take anticoagulants or have bleeding risks.
Nutrition During Opdivo Therapy
No single diet has been proven to improve Opdivo response, but studies consistently suggest that an overall healthy dietary pattern supports immune function and recovery.
Many oncology dietitians recommend:
- Plenty of colorful vegetables
- Fruits
- Whole grains
- Legumes
- Nuts
- Olive oil
- Fish
- Adequate protein
- Limiting ultra-processed foods
- Limiting added sugars
- Staying well hydrated
Patients experiencing diarrhea may temporarily require a lower-fiber diet until symptoms improve.
Should You Take Supplements?
Many patients ask whether supplements can enhance immunotherapy.
The answer is complicated.
Some supplements appear promising in laboratory research, but few have been tested rigorously in patients receiving checkpoint inhibitors.
General recommendations include:
✔ Tell your oncologist about every supplement you take.
✔ Avoid extremely high-dose antioxidant supplements unless specifically recommended.
✔ Correct documented deficiencies such as vitamin D, vitamin B12, or iron under medical supervision.
✔ Remember that “natural” does not automatically mean “safe.”
At PeopleBeatingCancer, we encourage an evidence-first approach: supplements should complement—not replace—standard cancer care, and decisions should be based on human clinical data whenever possible.
Living Well During Opdivo Treatment
Many patients continue working, traveling, and exercising while receiving Opdivo.
The following habits may help maintain quality of life:
- Aim for regular physical activity as tolerated.
- Prioritize restorative sleep.
- Stay hydrated, especially if diarrhea develops.
- Keep all laboratory and follow-up appointments.
- Report new symptoms promptly.
- Accept help from family, friends, or support groups.
- Maintain open communication with your oncology team.
Unlike chemotherapy, side effects from Opdivo can sometimes appear weeks or even months after treatment has ended, making continued vigilance important throughout survivorship.
Frequently Asked Questions About Opdivo (Nivolumab)
How long will I receive Opdivo?
Treatment duration depends on your cancer type, stage, and how well you respond. Many patients receive Opdivo every 2–6 weeks for up to two years, while others continue longer if they are benefiting and tolerating treatment. Your oncologist will individualize your treatment plan.
Is Opdivo chemotherapy?
No. Opdivo is an immune checkpoint inhibitor, a type of immunotherapy. Rather than directly killing cancer cells like chemotherapy, it helps your immune system recognize and attack them.
Can Opdivo cure cancer?
For some patients, Opdivo produces long-lasting remissions that persist years after treatment ends. While it is not considered a cure for most advanced cancers, it has significantly improved survival in melanoma, lung cancer, kidney cancer, Hodgkin lymphoma, and several other cancers.
Does everyone respond to Opdivo?
No. Response rates vary depending on the cancer type, tumor biology, and biomarkers such as PD-L1 expression and MSI-H/dMMR status. Researchers continue to study additional biomarkers that may better predict benefit.
What happens if Opdivo stops working?
Your oncologist may recommend:
- another immunotherapy
- chemotherapy
- targeted therapy (if appropriate)
- a clinical trial
- radiation therapy
- surgery in selected situations
Treatment decisions depend on the specific cancer and overall health.
Can I exercise while receiving Opdivo?
For most patients, yes.
Regular physical activity has been associated with:
- less fatigue
- improved mood
- better cardiovascular fitness
- better physical functioning
- improved quality of life
Always discuss exercise limitations with your oncology team, especially if you develop lung, heart, or muscle inflammation.
Can I receive vaccines?
Many inactivated vaccines (such as the annual influenza vaccine) are appropriate during immunotherapy, but timing and individual circumstances matter. Live vaccines are generally avoided in certain situations. Always discuss vaccinations with your oncology team before receiving them.
Opdivo vs. Keytruda
| Feature | Opdivo (Nivolumab) | Keytruda (Pembrolizumab) |
|---|---|---|
| Drug class | PD-1 inhibitor | PD-1 inhibitor |
| FDA approval | 2014 | 2014 |
| Mechanism | Blocks PD-1 receptor | Blocks PD-1 receptor |
| Administration | IV infusion | IV infusion |
| Typical schedule | Every 2–6 weeks | Every 3–6 weeks |
| Cancer types | Melanoma, lung, kidney, bladder, head & neck, GI, Hodgkin lymphoma, others | Broad range including melanoma, lung, bladder, cervical, endometrial, MSI-H tumors, and others |
| Combination therapy | Frequently combined with ipilimumab | Frequently combined with chemotherapy or targeted therapy |
| Common side effects | Similar | Similar |
| Serious immune toxicities | Similar | Similar |
Bottom line: Both drugs have transformed cancer care. The choice between them is generally based on the specific cancer, FDA-approved indications, biomarkers, and clinical trial evidence rather than one drug being universally “better.”
PeopleBeatingCancer Treatment Report Card
| Category | Rating | Comments |
|---|---|---|
| Evidence for treating cancer | ★★★★★ | Strong evidence across multiple cancer types |
| Overall survival benefit | ★★★★★ | Demonstrated in numerous Phase III trials |
| Progression-free survival | ★★★★★ | Significant in many approved indications |
| Quality-of-life impact | ★★★★☆ | Often better tolerated than cytotoxic chemotherapy |
| Short-term toxicity | ★★★☆☆ | Immune-related adverse events require monitoring |
| Long-term toxicity | ★★★☆☆ | Endocrine effects may persist |
| Evidence for complementary supportive care | ★★★★★ | Strong evidence for exercise, nutrition, sleep, stress reduction |
| Cost | ★☆☆☆☆ | High acquisition cost; insurance coverage varies |
| Overall PBC Rating | 9.4 / 10 | Excellent treatment for appropriately selected patients |
How PeopleBeatingCancer Evaluates Cancer Treatments
| Criterion | What We Look For |
|---|---|
| Human clinical evidence | Randomized trials and meta-analyses whenever available |
| Magnitude of benefit | Survival, recurrence reduction, symptom control, or quality of life |
| Safety | Frequency and severity of adverse events |
| Strength of evidence | Preference for high-quality human studies over laboratory or animal data |
| Patient practicality | Cost, accessibility, and ease of use |
| Shared decision-making | Whether treatment supports informed discussions between patients and clinicians |
Our goal is to help patients understand both the potential benefits and limitations of every therapy while encouraging informed conversations with their healthcare team.
Key Takeaways
- Opdivo is an immune checkpoint inhibitor that has significantly improved outcomes for many cancers.
- Because it stimulates the immune system, it can cause inflammation in healthy organs.
- Most immune-related side effects can be managed successfully when recognized early.
- Regular communication with your oncology team is essential throughout treatment.
- Healthy lifestyle habits—including physical activity, good nutrition, restorative sleep, and stress management—may improve quality of life during treatment.
- Evidence-based complementary therapies should support, not replace, conventional cancer care.
- Some patients experience exceptionally durable responses that persist long after treatment ends.
- The most important risks are immune-related adverse events, which are generally manageable when recognized and treated promptly.
To learn more:
To prepare for Opdivo–
- Integrative Oncology
- Complementary Cancer Therapies
- Cancer Prehabilitation
- Gut Microbiome and Cancer Side Effects
- Vitamin D and Cancer
Opdivo- Induced side effects-
- Chemotherapy-Induced Peripheral Neuropathy
- Chemotherapy-Induced Constipation and Diarrhea
- Hand-Foot Syndrome (contrast with taxane neuropathy)
- Chemotherapy-induced Skin Damage
- Chemotherapy-induced hearing loss
- Chemotherapy-induced Cardiomyopathy
- Chemotherapy-induced Fatigue
- Chemotherapy-Induced Anemia
- Enhance Blood Counts Naturally
- Electrolyte Disorders During Chemotherapy
- Exercise During Chemotherapy
- Anti-Inflammatory Diet for Cancer Patients
- Managing Cancer Treatment Side Effects (hub page)
- Financial Toxicity During Cancer Treatment
Lifestyle Post Therapy
Cancer-Specific Hubs
- Melanoma
- Lung Cancer
- Kidney Cancer
- Bladder Cancer
- Head and Neck Cancer
- Esophageal Cancer
- Colorectal Cancer
- Hodgkin Lymphoma
Selected Research
Immune Checkpoint Inhibitors
- Topalian SL, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med. 2012.
- Brahmer JR, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell NSCLC. N Engl J Med. 2015.
- Motzer RJ, et al. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma. N Engl J Med. 2015.
- Larkin J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015.
- Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (current versions by disease site).
- U.S. Food and Drug Administration. Opdivo (nivolumab) Prescribing Information.
- Opdivo (Nivolumab) for Cancer
Final Thoughts
For many patients, Opdivo represents one of the most significant advances in modern cancer treatment. By helping the immune system recognize and attack cancer cells, it has changed expectations for diseases that once had very limited treatment options.
At the same time, successful treatment requires partnership. Patients who understand the goals of therapy, recognize early warning signs of immune-related side effects, and maintain healthy lifestyle habits are better positioned to navigate treatment safely and confidently.
At PeopleBeatingCancer, our mission is to help patients make informed, evidence-based decisions. Conventional treatments like Opdivo have an important role in cancer care, and supportive strategies—including nutrition, exercise, sleep, stress reduction, and appropriate complementary therapies—can help many patients maintain quality of life throughout their cancer journey.
Opdivo (Nivolumab) for Cancer